Published Date: 16 Feb 2023
How is the SARS-CoV-2 mRNA antibody similar to the P.1 gamma strain and other strains?
Read Full NewsMerck's MK-2214 shows promise in early Alzheimer’s trials, earning FDA fast-track status for its safety and potential efficacy in slowing disease progression.
New STIRUS data unveiled at AES 2025 demonstrate meaningful real-world reductions in seizures, status epilepticus, and healthcare needs with stiripentol in Dravet syndrome.
New findings reveal the challenges of treating pediatric epileptic encephalopathy with NBI-827104, highlighting the need for effective therapies.
5 FDA Headlines You Missed in November 2025
1.
Emicizumab in Infants With Hemophilia A: Safe and Effective Use.
2.
In leukemia, allogeneic HCT is beneficial following primary induction failure.
3.
More People Than Previously Believed Have Schizophrenia.
4.
A smartphone app enhances the tracking of recovery following breast and gynecologic oncology surgery, according to JAMA.
5.
Is Laughter Good for Blood Glucose Control?
1.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
2.
Cancer Care Advances: Metformin, Digital Tools, and Artificial Renal Support
3.
Exploring the Causes and Treatments of Bacterial Keratitis: A Comprehensive Guide
4.
A Visual Journey Through Penile Cancer: Examining the Impact of Photos
5.
Advancing Medical Oncology: Education, Certification, Clinical Trials, and Evolving Treatment Pathways
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
2.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management
3.
Current Scenario of Cancer- Palliative Care to Close the Care Gap
4.
A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation